Myriad Genetics, Inc. announced that a study published in the Journal of Clinical Psychopharmacology found that the GeneSight® Psychotropic Test significantly reduced psychiatric hospitalizations in ...

Myriad Genetics, Inc., a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six prospective controlled studies that included 3,532 ...

Accelerated repetitive transcranial magnetic stimulation appears to be effective for treatment-resistant depression.

A depression drug candidate that’s a key part of Johnson & Johnson’s neuroscience strategy has failed a Phase 3 clinical trial, the latest dose of disappointing news for an emerging class of medicines ...

Patients who experienced a formulary-related rejection of cariprazine for adjunctive treatment of major depressive disorder had significantly higher hospitalization rates than those with approved ...

Patients with major depressive disorder and patients with inflammatory skin diseases like atopic dermatitis share similar ...